Eisai Co., Ltd. and Biogen Inc. have introduced promising real-world findings on the long-term therapy persistence of their Alzheimer’s drug, lecanemab. The evaluation, introduced on the twentieth International Conference on Alzheimer’s and Parkinson’s Diseases in Copenhagen, revealed that almost all sufferers proceed therapy past the preliminary 18 months.
The examine, using the PurpleLab CLEAR Claims database, assessed 10,763 people within the U.S. who obtained intravenous lecanemab between January 2023 and November 2025. The findings confirmed that 78.4% of sufferers remained on therapy at 18 months, with persistence charges of 71.7% at 20 months and 67.3% at 24 months.
These outcomes align with the Phase III Clarity AD examine, the place 94% of sufferers opted to proceed with a long-term extension examine after finishing 18 months of therapy. The evaluation means that potential delays as a consequence of MRI monitoring and different elements didn’t considerably influence dosing adherence.
Lecanemab, developed by a collaboration between Eisai and BioArctic, targets amyloid-beta protofibrils, believed to contribute to Alzheimer’s development. The drug has been authorized in 53 nations, with upkeep dosing sanctioned in seven nations, together with the U.S. and China.
In scientific trials, lecanemab demonstrated a notable discount in cognitive decline, with a 1.01-point lower on the Clinical Dementia Rating-Sum of Boxes scale over three years, in comparison with the Alzheimer’s Disease Neuroimaging Initiative cohort. This profit elevated to a 1.75-point discount after 4 years.
The ongoing Phase 3 AHEAD 3-45 examine and the Tau NexGen scientific examine proceed to discover lecanemab’s potential in preclinical and dominantly inherited Alzheimer’s illness, respectively.